drugset
drugset / Trial / NCT07197554

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

NCT07197554 ↗

Phase 1 Recruiting 171 enrolled SEED Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies

Timeline

Start
2025-12-01
Primary completion
2029-12-31
Completion
2029-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject ST-01156 Small molecule — Oral

Indications

Ewing sarcoma biliary tract cancer hepatocellular carcinoma